Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with PertuzumabOtto Metzger, Ian E. Krop, Giuseppe Viale et al.|Cancer Discovery|2021Cited by 241
High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trialGiulia Viale, Fátima Cardoso, Femke A. de Snoo et al.|Annals of Oncology|2014Cited by 65
HER2 heterogeneity and treatment response–associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trialZheqi Li, Kornélia Polyák, Otto Metzger et al.|Journal of Clinical Investigation|2024Cited by 29